Nutritional products maker Herbalife's beats Q2 adjusted EPS estimates, raises full-year guidance

Reuters
Aug 07
Nutritional products maker Herbalife's beats <a href="https://laohu8.com/S/QTWO">Q2</a> adjusted EPS estimates, raises full-year guidance

Overview

  • Herbalife Q2 net sales of $1.3 bln down 1.7% yr/yr, flat in constant currency

  • Adjusted EBITDA of $173.6 mln exceeds company guidance, adjusted EPS beats market estimates

  • Co raises full-year net sales and adjusted EBITDA guidance

Outlook

  • Herbalife raises full-year 2025 net sales growth guidance to (1.0)% to +3.0% YoY

  • Company increases full-year 2025 adjusted EBITDA guidance to $640 mln - $660 mln

  • Herbalife reduces full-year 2025 capital expenditures guidance to $75 mln - $95 mln

  • Company sees Q3 2025 net sales growth of +0.5% to +4.5% YoY

Result Drivers

  • PRODUCT LAUNCHES - Launch of MultiBurn supplement and beta version of Pro2col app seen as pivotal steps in innovation, per CEO Stephan Gratziani

  • CURRENCY HEADWINDS - Net sales impacted by 170 basis points of FX headwinds, flat year-over-year on constant currency basis

  • DISTRIBUTOR ENGAGEMENT - Distributor growth initiatives supported engagement but new distributor growth was flat year-over-year

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Adjusted EPS

Beat

$0.59

$0.38 (2 Analysts)

Q2 EPS

$0.48

Q2 Net Income

$49.30 mln

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the food processing peer group is "buy."

  • Wall Street's median 12-month price target for Herbalife Ltd is $9.00, about 5.1% below its August 5 closing price of $9.46

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nBw7BXRjwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10